157 related articles for article (PubMed ID: 36356295)
1. Pituitary-testis axis dysfunction following adjuvant androgen deprivation therapy.
Abildgaard J; Vincent Stroomberg H; Kirstine Bang A; Albrethsen J; Smedegaard Kruuse L; Juul A; Brasso K; Røder A; Jørgensen N
Endocr Relat Cancer; 2023 Jan; 30(1):. PubMed ID: 36356295
[TBL] [Abstract][Full Text] [Related]
2. Developments in the control of testicular function.
Swerdloff RS; Wang C; Bhasin S
Baillieres Clin Endocrinol Metab; 1992 Apr; 6(2):451-83. PubMed ID: 1377467
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of testosterone recovery in clinically localized prostate cancer patients treated with radical prostatectomy and subsequent short-term adjuvant androgen deprivation therapy.
Dai B; Qu YY; Kong YY; Ye DW; Yao XD; Zhang SL; Zhang HL; Yang WY
Asian J Androl; 2013 Jul; 15(4):466-70. PubMed ID: 23708460
[TBL] [Abstract][Full Text] [Related]
5. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
6. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
[TBL] [Abstract][Full Text] [Related]
7. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
[TBL] [Abstract][Full Text] [Related]
8. [Endocrine profiles and gonadotropin response to Gn-RH of men with testicular cancer].
Watanabe M; Fuji K; Suzuki K; Kitamura T; Okumura D; Kasahara T; Igarashi T; Masuyama T; Hiramori T; Higaki M; Yoshida H
Nihon Hinyokika Gakkai Zasshi; 2003 Jul; 94(5):543-50. PubMed ID: 12910930
[TBL] [Abstract][Full Text] [Related]
9. Advances with androgen deprivation therapy for prostate cancer.
Yu EM; Aragon-Ching JB
Expert Opin Pharmacother; 2022 Jun; 23(9):1015-1033. PubMed ID: 35108137
[TBL] [Abstract][Full Text] [Related]
10. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
Behre HM; Nashan D; Hubert W; Nieschlag E
J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
[TBL] [Abstract][Full Text] [Related]
11. Elucidation of the mechanism of suppressed steroidogenesis during androgen deprivation therapy of prostate cancer patients using a mouse model.
Taniguchi H; Katano T; Nishida K; Kinoshita H; Matsuda T; Ito S
Andrology; 2016 Sep; 4(5):964-71. PubMed ID: 27230983
[TBL] [Abstract][Full Text] [Related]
12. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.
Wang Y; Dai B; Ye DW
Asian J Androl; 2017; 19(2):178-183. PubMed ID: 26975487
[TBL] [Abstract][Full Text] [Related]
13. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
14. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
15. Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE.
Aaronson D; Cowan J; Carroll P; Konety B
BJU Int; 2010 Apr; 105(7):951-5. PubMed ID: 19889066
[TBL] [Abstract][Full Text] [Related]
16. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.
Schulman C; Irani J; Aapro M
BJU Int; 2012 Jun; 109 Suppl 6():13-21. PubMed ID: 22672121
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer.
Nishiyama T
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):179-90. PubMed ID: 22269996
[TBL] [Abstract][Full Text] [Related]
18. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
[TBL] [Abstract][Full Text] [Related]
19. An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer.
Roy S; Zaorsky NG; Bagshaw HP; Berlin A; Tree A; Turner S; Koontz B; Nguyen P; Chen R; Dess RT; Jackson WC; Kishan AU; Stish B; Nagar H; Posadas E; Tran PT; Solanki A; Shore ND; Guo G; Ponsky L; Shoag JE; Morgans AK; Garcia JA; Showalter TN; Feng FY; Spratt DE
Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):278-289. PubMed ID: 34923058
[TBL] [Abstract][Full Text] [Related]
20. The impact of long-term androgen deprivation therapy on cognitive function and socioeconomic decision making in prostate cancer patients.
Holtfrerich SKC; Knipper S; Purwins J; Castens J; Beyer B; Schlomm T; Diekhof EK
Psychooncology; 2020 Aug; 29(8):1338-1346. PubMed ID: 32539186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]